Annovis Bio, Inc. announced a definitive agreement for the purchase of 4,000,000 shares of its common stock at $1.50 per share in a registered direct offering, totaling approximately $6 million. The closing is expected on October 13, 2025. H.C. Wainwright & Co. is the exclusive placement agent for the offering.

The Company plans to use the net proceeds for working capital and general corporate purposes. The offering is made under a shelf registration statement and will be conducted through a prospectus supplement available on the SEC’s website.

Annovis Bio is dedicated to developing therapies for neurodegenerative diseases like Alzheimer’s and Parkinson’s.

Read more at GlobeNewswire: Annovis Announces $6 Million Registered Direct Offering of